Taro Pharmaceutical Indus... (TARO)
NYSE: TARO
· Real-Time Price · USD
42.98
0.01 (0.02%)
At close: Jun 21, 2024, 9:59 PM
Taro Pharmaceutical Industries Cash Flow Statement
Financials in USD. Fiscal
year is
April - March.
| Fiscal Year | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 | Q2 2022 | Q1 2022 | Q4 2021 | Q3 2021 | Q2 2021 | Q1 2021 |
| Period Ending | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 |
Net Income | 53.87M | 45.7M | 32.76M | 21.4M | 25.45M | 45.94M | 64.98M | 91.11M | 58.27M | 1.98M | 8.7M | 30.45M | -400.74M | -317.44M | -282.8M | -271.65M |
Depreciation & Amortization | 31.09M | 33.68M | 33.63M | 33.04M | 32.13M | 27.99M | 27.11M | 26.55M | 25.91M | 25.59M | 25.11M | 24.45M | 23.68M | 22.62M | 22.09M | 21.88M |
Stock-Based Compensation | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Other Working Capital | 15.35M | -47.53M | -54.77M | -59.1M | -121.12M | 196.84M | -453.55K | -118.19M | -8.29M | -187.81M | 3.44M | 34.09M | 464.89M | 372.22M | 400.64M | 499.4M |
Other Non-Cash Items | -16.19M | -20.11M | -7.85M | -5.29M | 3.06M | 21.83M | 15.31M | 16.21M | 12.96M | 10.41M | 10.02M | 4.41M | 584K | 978K | -5.89M | -6.39M |
Deferred Income Tax | 19.57M | 17.38M | 17.1M | 16.77M | 16.8M | 12.81M | 8.52M | 14.37M | 23.2M | 8.47M | 18.11M | -24.8M | -38.41M | -22.22M | -32.31M | 2.29M |
Change in Working Capital | 29.19M | 66.22M | 56.85M | 39.42M | -37.91M | -84.43M | -304.26M | -408.96M | -279.04M | -195.34M | 23.96M | -8.86M | 460.66M | 360.37M | 399M | 506.98M |
Operating Cash Flow | 130.46M | 142.87M | 124.71M | 97.56M | 31.75M | 16.36M | -188.34M | -260.72M | -158.7M | -148.9M | 85.89M | 25.65M | 45.77M | 44.31M | 100.1M | 253.11M |
Capital Expenditures | -56.27M | -56.87M | -30.19M | -24.58M | -19.85M | -14.11M | -9.61M | -10.22M | -12.04M | -12.06M | -14.05M | -15.88M | -17.14M | -22.35M | -23.77M | -25.59M |
Cash Acquisitions | -1K | 171K | 88.56M | 157.99M | 121.16M | 29.12M | -59.27M | -128.7M | -91.87M | n/a | n/a | n/a | n/a | -952.44M | -952.44M | -952.44M |
Purchase of Investments | -1.52M | -848.17M | -924.11M | -1B | -972.15M | -137.92M | -72.7M | -54.24M | -66.67M | -52.73M | -42.02M | -12.5M | -40.83M | -77.2M | -194.1M | -301.52M |
Sales Maturities Of Investments | 147.01M | 1.05B | 924.65M | 829.51M | 866.45M | 3.06M | 15.52M | 36.94M | n/a | n/a | n/a | n/a | n/a | 952.42M | 952.42M | 952.42M |
Other Investing Acitivies | 32.74M | 84.02M | -120.48M | -189.9M | -121.16M | -212.86M | -135.2M | -95.33M | -144.73M | -28.09M | 943K | 113.14M | 84.82M | 60.08M | -76.09M | -266.18M |
Investing Cash Flow | 89.22M | 148.21M | -29.65M | -199.01M | -125.56M | -240.84M | -158.67M | -119.4M | -170.58M | -40.03M | -13M | 97.33M | 67.74M | 1.39M | -135.23M | -327.11M |
Debt Repayment | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Common Stock Repurchased | n/a | n/a | n/a | n/a | n/a | n/a | n/a | -6.62M | -24.93M | -45.89M | -49.13M | -42.52M | -24.2M | -3.4M | -26.98M | -26.98M |
Dividend Paid | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Other Financial Acitivies | n/a | n/a | n/a | n/a | -18.32M | -18.32M | -18.32M | -24.93M | -24.93M | -45.89M | -49.13M | -42.52M | -24.2M | -3.4M | -26.98M | -26.98M |
Financial Cash Flow | n/a | n/a | n/a | n/a | -18.32M | -18.32M | -18.32M | -24.93M | -24.93M | -45.89M | -49.13M | -42.52M | -24.2M | -3.4M | -26.98M | -26.98M |
Net Cash Flow | 208.41M | 290.44M | 93.82M | -101.64M | -96.64M | -226.13M | -348.48M | -389.09M | -354.04M | -234.81M | 24.87M | 82.84M | 91.82M | 43.56M | -61.87M | -100.94M |
Free Cash Flow | 74.19M | 86M | 94.52M | 72.97M | 11.9M | 2.25M | -197.95M | -270.94M | -170.74M | -160.96M | 71.84M | 9.78M | 28.63M | 21.96M | 76.33M | 227.52M |